Akeso: We’re The Leaders In Bispecific Cancer Immunotherapies

 
• By Andrew McConaghie

The Chinese company is building on its success with ivonescimab and believes it can stay ahead of its rivals and develop into a global company.

The Shenzhen middle channel bridge in the Pearl river delta connects the cities of Shenzen and Zhongshan, where Akeso is headquartered. (Shutterstock)

More from Clinical Trials

More from Therapy Areas